Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208421
Title: | Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party |
Author: | Penack, Olaf Peczynski, Christophe Koenecke, Christian Polge, Emmanuelle Sanderson, Robin Yakoub Agha, Ibrahim Fegueux, Nathalie Daskalakis, Michael Collin, Matthew Dreger, Peter Kröger, Nicolaus Schanz, Urs Bloor, Adrian Ganser, Arnold Besley, Caroline Wulf, Gerald G. Novak, Urban Moiseev, Ivan Schoemans, Hélène Basak, Grzegorz W. Chabannon, Christian Sureda, Anna Glass, Bertram Peric, Zinaida |
Keywords: | Limfomes Receptors cel·lulars Lymphomas Cell receptors |
Issue Date: | 27-Sep-2023 |
Publisher: | Frontiers Media SA |
Abstract: | We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of >= grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1252811 |
It is part of: | Frontiers in Immunology, 2023, vol. 14 |
URI: | http://hdl.handle.net/2445/208421 |
Related resource: | https://doi.org/10.3389/fimmu.2023.1252811 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-14-1252811.pdf | 571.52 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License